BSRC Fleming is one of the most rapidly developing research centers in Greece. It was established in 1998 and today is
actively involved in cutting edge research in biomedical
sciences. The Center currently hosts 14 research groups in 4 Institutes
covering the areas of
immunology,
molecular biology & genetics
,
molecular oncology,
cellular and developmental biology.
Fleming has gained extensive visibility in the European Research
Area through state of the art research programs in basic, as
well as translational and applied science in biology,
biomedicine and biotechnology (visit the Center's
achievements page).
Fleming is a non-profit organisation and operates under the supervision of the General Secretariat for Research and Technology (GSRT) of the Hellenic Ministry of Education. In 2005 Fleming was proclaimed a “Scientific Center of Excellence” following a GSRT sponsored site visit by an international review panel of distinguished scientists.
Highlights
![]() |
29/12/2011. Fleming Researchers (Kontoyiannis Group) revealed the importance of the mRNA regulator HuR, in inflammation supporting tumor development. Using transgenic systems for the deletion or overexpression of HuR in inflammatory cells, they unraveled unprecedented effects in mRNA regulation and demonstrated that enhancing HuR activity may be of clinical benefit in the battle against pathologic inflammation and colitis associated cancer. See [Article; http://www.jci.org/articles/view/45021 ] and related [Commentary; http://www.jci.org/articles/view/61677 ]. |
![]() |
13/12/2011. Fleming researcher receives ERC Advanced Grant. Iannis Talianidis (Director of IMBG) was awarded the prestigious ERC Advanced Investigator Grant to study the function of histone modifying enzymes in disease. The award will aid in reinforcing the position of the Institute as a center of excellence in the field of epigenetics. |
|
17/11/2011. Fleming’s researchers have discovered a functional mutation in the mouse Rankl gene that causes Autosomal Recessive Osteopetrosis, a lethal inherited disorder in humans characterized by increased bone mass. Molecular characterization of the causal mutation identified an amino acid critical for RANKL function providing a basis for the design and evaluation of novel RANKL inhibitors that apply in bone-resorptive diseases like osteoporosis. More info |
|
Introducing
Biomedcode Hellas SA. |
|
|
|
The Center has established six core facilities to offer internal and external users direct access to its research infrastructures. The animal house facility, protein chemistry lab, expression profiling facility, transgenic facility, flow cytometry facility, innovation and enterprise unit, genotyping facility and BioIT unit are actively involved in collaborations with both academic and industrial partners. |
| More highlights... | |
International Collaborations
![]() |
The BSRC Fleming participates in a number of International programs. Such collaborations are of significant importance for the exchange and dissemination of knowledge and expertise as well as bring together major groups around the world for the study and therapy of human disease. |
| Read more on International Collaborations... | |





